Riskpilot← Back to searchSign inGet full accessXVIVO Perfusion Lund AB
ABDissolvedOrg 5567611701Other research and experimental development on natural sciences and engineering · NACE 7219Est. 20088 employees
Revenue 2022
SEK 18,2M
+14% vs 2021
EBITDA margin
-27.4%
-181% vs 2021
Equity ratio
61.1%
Financial strength
Net profit 2022
SEK -5,4M
-132% vs 2021
| Revenue | SEK 18,2M | +14% |
| EBITDA | SEK -5M | -181% |
| Net profit | SEK -5,4M | -132% |
| Total assets | SEK 15,4M | -18% |
| Equity | SEK 9,4M | -37% |
| Employees | 8 | — |
Legal name
XVIVO Perfusion Lund AB
Org number
5567611701
Legal form
Aktiebolag
NACE code
7219 · Other research and experimental development on natural sciences and engineering
Founded
2 juli 2008
Share capital
SEK 2 509 000
Employees
8 (FTE)
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva utveckling, marknadsföring och försäljning av medicintekniska produkter och lösningar för transplantation samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue | 16 727 | 23 047 | 12 694 | 16 005 | 18 222 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −6 181 | −7 021 | −6 065 | −1 779 | −4 996 |
| Depreciation & amort. | −1 102 | −1 214 | −708 | −571 | −406 |
| EBIT | −7 283 | −8 235 | −6 773 | −2 350 | −5 402 |
| Net financials | 17 | 40 | −91 | 9 | −16 |
| Profit before tax | 11 034 | 55 | −6 865 | −2 340 | −5 418 |
| Tax | −0 | −35 | −12 | −0 | −0 |
| Net profit | 11 034 | 20 | −6 877 | −2 340 | −5 418 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Total assets | 28 789 | 30 346 | 21 597 | 18 745 | 15 387 |
| Equity | 24 020 | 24 041 | 17 164 | 14 824 | 9 406 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 4 768 | 6 305 | 4 433 | 3 922 | 5 981 |
| Total debt | 4 768 | 6 305 | 4 433 | 3 922 | 5 981 |
EBITDA margin
-27.4%
This company
15.8%
Market median
-273% vs market
20182022
Equity ratio
61.1%
This company
38.2%
Market median
+60% vs market
20182022
Return on equity
-57.6%
This company
18.4%
Market median
-413% vs market
20182022
Net profit margin
-29.7%
This company
8.1%
Market median
-467% vs market
20182022
Asset turnover
1.18×
This company
1.12×
Market median
+5% vs market
20182022
Debt / equity
0.64×
This company
0.62×
Market median
+3% vs market
20182022
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
CB Chief Executive Officer | Chief Executive Officer | 2022 |
JD Chief Auditor | Chief Auditor | 2020 |
| Former (1) | ||
JO Chief Auditor | Chief Auditor | 2020 – 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
| Former (4) | ||
| Chairman | 2020 – 2022 | |
| Deputy Board Member | 2020 – 2022 | |
| Deputy Board Member | 2022 – 2022 | |
| Chairman | 2020 – 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Xvivo Perfusion Aktiebolag
XVIVO Perfusion Lund AB Board members of XVIVO Perfusion Lund AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Christoffer Björn Rosenblad | Chief Executive Officer | 0 companies |
| Johan Daniel Haglund | Chief Auditor | 0 companies |
| Jan Olof Malm | Chief Auditor | 0 companies |
| Johan Martin Holmström | Deputy Board Member | 0 companies |
| Dag Olov Andersson Tilk | Chairman | 0 companies |
| Ewert Christer De Flon | Deputy Board Member | 0 companies |
| Niklas Kristoffer Nordström | Deputy Board Member | 0 companies |
| Magnus Henrik Ludvig Nilsson | Chairman | 0 companies |